创新医疗管理股份有限公司 关于召开 2023 年度网上业绩说明会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚假 记载、误导性陈述或者重大遗漏。 创新医疗管理股份有限公司（以下简称"公司"）已于 2024 年 4 月 13 日在 巨潮资讯网（http://www.cninfo.com.cn/）上披露了《2023 年年度报告》及《2023 年年度报告摘要》。 为便于广大投资者进一步了解公司 2023 年年度经营情况，公司定于 2024 年 5 月 6 日（星期一）15:00 至 17:00 在"约调研"小程序举行 2023 年度网上 业绩说明会。本次网上业绩说明会将采用网络远程的方式举行，投资者可登陆"约 调研"小程序参与互动交流。为广泛听取投资者的意见和建议，提前向投资者征 集问题，提问通道自发出公告之日起开放。 参与方式一：在微信小程序中搜索"约调研"； 参与方式二：微信扫一扫以下二维码： 证券代码：002173 证券简称：创新医疗 公告编号：2024-021 员会有调整） 敬请广大投资者积极参与。 特此公告。 创新医疗管理股份有限公司 董 事 会 2024 年 4 月 27 日 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 201,344,535.99, a decrease of 1.40% compared to CNY 204,206,456.23 in the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 2,977,863.39, representing a decline of 37.87% from a loss of CNY 2,159,886.00 in the previous year[4] - The company's net profit excluding non-recurring gains and losses was a loss of CNY 2,708,735.09, a decline of 876.63% from a profit of CNY 277,355.34 in the same period last year[4] - The weighted average return on equity was -0.16%, compared to -0.11% in the previous year, indicating a slight deterioration in profitability[4] - The company reported non-recurring losses totaling CNY 269,128.30 for the quarter, primarily due to other operating expenses[6] - The company's net loss for Q1 2024 was CNY 1,307,215,574.97, slightly increasing from CNY 1,304,237,711.58 in the previous quarter[13] - Operating profit was reported at -¥2,112,325.21, a decline from -¥224,986.20 in the previous period, reflecting a significant deterioration in operational performance[16] - Total revenue from operating activities was ¥182,904,706.98, down from ¥222,244,830.87, representing a decrease of about 17.7%[19] Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 17,663,752.00, a significant decrease of 242.76% compared to a positive cash flow of CNY 12,372,882.62 in the same period last year[4] - The company's cash and cash equivalents at the end of Q1 2024 were CNY 543,823,060.69, a decrease of 3.4% from CNY 563,083,485.71 at the beginning of the quarter[12] - The net cash flow from operating activities was -¥17,663,752.00, contrasting with a positive cash flow of ¥12,372,882.62 in the previous period[19] - Cash and cash equivalents at the end of the period totaled ¥529,951,281.78, an increase from ¥249,019,635.01 at the beginning of the period, showing a net increase of ¥280,931,646.77[19] - The company generated ¥304,563,287.72 from investment activities, significantly higher than the previous period's cash inflow of ¥215,000.00[19] - The net cash flow from financing activities was ¥10,452,995.48, compared to a negative cash flow of -¥6,065,486.72 in the previous period, indicating improved financing conditions[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,264,284,369.08, a decrease of 0.75% from CNY 2,281,472,772.53 at the end of the previous year[5] - The equity attributable to shareholders was CNY 1,867,174,252.09, down 0.16% from CNY 1,870,152,115.48 at the end of the previous year[5] - The total assets of the company at the end of Q1 2024 were CNY 2,264,284,369.08, a decrease of 0.8% from CNY 2,281,472,772.53 at the beginning of the quarter[13] - The total liabilities decreased to CNY 396,176,814.89, down 3.4% from CNY 410,385,658.35 at the beginning of the quarter[12] - The company's inventory decreased to CNY 37,726,419.22, down 9.9% from CNY 41,805,047.04 at the beginning of the quarter[12] - The company’s long-term equity investments decreased to CNY 14,345,628.32, down from CNY 15,219,218.88 at the beginning of the quarter, reflecting a decline of 5.7%[12] Earnings Per Share - The basic and diluted earnings per share were both negative CNY 0.0067, down 39.58% from negative CNY 0.0048 in the previous year[4] - Basic and diluted earnings per share were both reported at -¥0.0067, worsening from -¥0.0048 in the previous period[16] Other Information - The company has not disclosed any new product developments or market expansion strategies in this report[4] - The company has not undergone an audit for the first quarter report, which may affect the reliability of the financial data presented[21] - The company is set to implement new accounting standards starting in 2024, which may impact future financial reporting[20]

创新医疗管理股份有限公司 关于募集资金专户销户完成的公告 证券代码：002173 证券简称：创新医疗 公告编号：2024-019 创新医疗管理股份有限公司 董 事 会 2024 年 4 月 17 日 1 / 1 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 创新医疗管理股份有限公司（以下简称"公司"）于2024年4月11日召开了 第六届董事会第五次会议，审议通过了《关于募集资金使用完毕及注销募集资金 账户的议案》，同意对目前尚存的募集资金专户（海宁康华医院有限公司，中国 工商银行股份有限公司海宁支行，账号：1204085029201504833）进行销户处理。 具体内容详见公司2024年4月13日披露于《中国证券报》、《证券时报》、《证 券日报》、《上海证券报》及巨潮资讯网（www.cninfo.com.cn）的相关公告。 公司已于2024年4月16日完成了上述募集资金专户注销手续。公司、海宁康 华医院有限公司与保荐机构、相关银行签署的《募集资金四方监管协议》相应终 止。 特此公告。 ...

Business Transformation - The company reported a significant transformation from a single business model focused on pearl farming to a dual business model that includes high-quality medical services as its main operation[20]. - The company has expanded its operations to include hospital management consulting services, investment in the healthcare sector, and research and development of medical devices and pharmaceuticals[21]. - The company has established three subsidiaries: Jianhua Hospital, Kanghua Hospital, and Fuyuyuan Hospital, enhancing its presence in the healthcare industry[20]. - The company has committed to providing high-quality medical services as part of its strategic transformation[20]. Financial Performance - The company's operating revenue for 2023 was ¥805,585,526.56, representing a 13.51% increase compared to ¥709,698,070.78 in 2022[22]. - The net profit attributable to shareholders improved to -¥34,287,743.35 in 2023, a 53.30% reduction from -¥73,697,199.07 in 2022[22]. - The net cash flow from operating activities was ¥11,030,985.78, a significant turnaround from -¥24,445,528.60 in the previous year, marking a 145.12% increase[22]. - The basic earnings per share improved to -¥0.08, a 50.00% increase from -¥0.17 in 2022[22]. - Total assets at the end of 2023 were ¥2,281,472,772.53, down 2.48% from ¥2,339,662,759.53 at the end of 2022[22]. - The company reported a net asset attributable to shareholders of ¥1,870,152,115.48 at the end of 2023, reflecting a decrease of 1.78% from ¥1,904,313,052.88 in 2022[22]. Operational Challenges - The company emphasizes the importance of risk awareness in its future operational outlook, highlighting potential challenges[4]. - The company acknowledged uncertainty regarding its ability to continue as a going concern, as indicated by negative net profits over the last three years[24]. - The net profit attributable to shareholders for Q4 2023 was -¥20,072,977.57, indicating ongoing challenges in profitability[28]. - Non-operating losses totaled -¥6,285,167.14 for 2023, compared to a gain of ¥10,508,833.18 in 2022[29]. Market and Industry Trends - The healthcare market is projected to expand due to increasing healthcare demands driven by an aging population and heightened public health awareness[84]. - The company aims to enhance its management level and service quality through refined management practices and internal control systems[37]. - The company is committed to expanding its market presence and improving its competitive advantage through strategic partnerships and community health service networks[40]. Governance and Compliance - The company’s financial report is guaranteed to be true, accurate, and complete by its board of directors and management[4]. - The company maintained a fully independent operational structure, with no interference from the controlling shareholder in business, personnel, assets, or financial matters[98]. - The company’s governance practices align with the requirements set forth by the China Securities Regulatory Commission, with no significant discrepancies noted[97]. - The company has implemented a transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management[96]. Shareholder Relations - The company held 1 annual general meeting and 3 extraordinary general meetings during the reporting period, ensuring equal treatment of all shareholders, especially minority shareholders[95]. - The participation rate of investors in the 2023 first extraordinary general meeting was 30.23%, while the participation rate for the 2022 annual general meeting was 34.98%[101]. - The company’s management team includes experienced professionals, with the chairman holding 22,225,300 shares, reflecting significant personal investment in the company[102]. Employee Management - The total number of employees at the end of the reporting period was 2,749, with 686 doctors and 959 nurses[125]. - The company has implemented a performance-based salary incentive system to motivate employees[126]. - The company plans to continue internal and external training for medical staff to improve service quality[127]. Environmental Responsibility - The company integrates ecological and environmental protection into its development strategy, focusing on minimizing hospital waste and optimizing resource utilization[139]. - The company has committed to improving hospital environments and patient satisfaction through enhanced waste management and environmental practices[139]. Legal and Regulatory Matters - The company reported a provision of RMB 130.42 million for a legal dispute related to a financing lease contract, with RMB 30.32 million recognized as other income in the current period[148]. - The company is currently involved in ongoing litigation related to financing lease agreements, with no final judgment reached as of now[154]. - The company has taken effective measures to rectify issues pointed out in the warning letter from the regulatory authority[156]. Strategic Acquisitions and Investments - The company has completed two strategic acquisitions in the past year, enhancing its product portfolio and market presence[106]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $100 million allocated for potential mergers[112]. Future Outlook - Future outlook indicates a projected revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion strategies[109]. - The company expects a revenue growth of 10% for the next fiscal year, projecting revenues to reach approximately 1.32 billion RMB[115].

2023年度 环境、社会及公司治理（ESG）报告 Environmental、Social、Governance (ESG)Report 1 目 录 公共关系与 社会责任 环境保护与 可持续发展 相关利益方 权益保护 2024年度社会 05 06 07 08 责任工作目标 关于本报告 董事长寄语 公司简介 经营与管理 01 02 03 04 2 关于本报告 本报告是创新医疗管理股份有限公司对外发布的环境、 社会及公司治理（ESG）报告，本报告详细披露了公司及下属 医院于2023年在环境、社会及公司治理等方面履行社会责任的 实践，旨在向社会公众以及利益相关方进行说明，以期得到社 会各界更广泛的了解、支持与帮助。 报告周期：本报告为年度报告。 时间范围：本报告以2023年1月1日-2023年12月31日 为主，必要时追溯到创新医疗发展历程中的重要年份。 指代说明：为了便于表述和方便阅读，在本报告中， "创新医疗管理股份有限公司"以"创新医疗"、 "公司"、"我们"表示。 报告范围：本报告主体范围包括公司及子公司。 精神的开局之年，亦是创新医疗承 压前行、稳中有进的一年。我们坚 定履行社会责任，并在精益管理、 质量 ...

创新医疗管理股份有限公司 鉴证报告 创新医疗管理股份有限公司全体股东： 我们接受委托，对后附的创新医疗管理股份有限公司（以下简 称"贵公司"） 2023年度募集资金存放与使用情况专项报告（以下简 称"募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 贵公司董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第2号——上市公司募集资金管理和使用的监管要求 （2022年修订）》（证监会公告〔2022〕15号）、《深圳证券交易 所上市公司自律监管指引第1号——主板上市公司规范运作》以及 《深圳证券交易所上市公司自律监管指南第2号——公告格式》的相 关规定编制募集资金专项报告。这种责任包括设计、执行和维护与 募集资金专项报告编制相关的内部控制，确保募集资金专项报告真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对募集资金专项报告发 表鉴证结论。 三、工作概述 我们按照《中国注册会计师其他鉴证业务准则第3101号——历 史财务信息审计或审阅以外的鉴证业务》的规定执行了鉴证业务。 该准则要求我们遵守职业道德规范，计划和实施鉴证工作 ...

二、 监事会会议审议情况 与会监事就议案进行了审议、表决，一致通过了如下决议： （一）审议通过了《2023 年度监事会工作报告》。 创新医疗管理股份有限公司 第六届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、 监事会会议召开情况 证券代码：002173 证券简称：创新医疗 公告编号：2024-010 创新医疗管理股份有限公司（以下简称"公司"）第六届监事会于 2024 年 4 月 11 日召开了第十一次会议。本次会议以现场和通讯表决相结合的方式在公 司会议室召开。会议通知于 2023 年 4 月 1 日以书面形式发出。本次会议由寿田 光监事会主席主持，本次会议应出席监事 3 人，实际出席现场会议监事 2 人，李 小龙监事以通讯表决方式对会议所议事项进行了审议和表决。本次会议召开符合 《公司法》及公司《章程》的规定，合法有效。 本议案须提交公司 2023 年年度股东大会审议。 （二）审议通过了《2023 年年度报告》全文及摘要。 公司《第六届监事会第十一次会议决议》。 监事会认为：董事会编制和审核公司 2023 年年度报告的程 ...

创新医疗管理股份有限公司 审计报告及财务报表 二○二三年度 创新医疗管理股份有限公司 审计报告及财务报表 （2023 年 01 月 01 日至 2023 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-4 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-108 | 审 计 报 告 信会师报字[2024]第 ZF10247 号 创新医疗管理股份有限公司全体股东： 一、 审计意见 我们审计了创新医疗管理股份有限公司（以下简称创新医疗）财 务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公 司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的 规定编 ...

创新医疗管理股份有限公司 2023 年度内部控制自我评价报告 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下 简称企业内部控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法， 在内部控制日常监督和专项监督的基础上，我们对公司截止2023年12月31日（内部控制评 价报告基准日）的内部控制有效性进行了评价。 一、 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效 性，并如实披露评价报告是公司董事会的责任。监事会对董事会建立和实施内部控 制进行监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、监事会 及董事、监事、高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或 重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信 息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有 局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化可能导致内 部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制评价结 ...

证券代码：002173 证券简称：创新医疗 公告编号：2024-013 创新医疗管理股份有限公司 关于聘请 2024 年度审计机构的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 立信会计师事务所（特殊普通合伙）（以下简称"立信会计师事务所"、"立 信"）对创新医疗管理股份有限公司（以下简称"公司"）2023 年度财务报告出 具了无保留意见审计报告。 公司于 2024 年 4 月 11 日召开的第六届董事会第五次会议，审议通过了《关 于聘请 2024 年度审计机构的议案》，公司拟续聘立信会计师事务所为公司 2024 年度审计机构。现将相关事宜公告如下： 一、拟聘任会计师事务所的情况说明 立信会计师事务所具有证券相关业务执业资格，在该所担任公司审计机构期 间，所出具的报告客观、公正地反映了公司各期的财务状况和经营成果，对公司 的财务规范运作、内部控制制度的建设和执行起到了重要的指导作用，勤勉尽责 地履行了双方所规定的责任与义务。立信会计师事务所具备足够的独立性、专业 胜任能力、投资者保护能力，续聘立信会计师事务所为公司 2024 年度审计机构 ...